This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics...
The past week was busy for the biotech sector with several pipeline updates as the reporting cycle ended. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) won the FDA approval for...
Shares of clinical-stage biopharmaceutical company Zafgen, Inc. (NASDAQ:ZFGN) slumped 40.5% after the company announced that the FDA has placed a clinical hold on the...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Neutral||Neutral||Sell||Strong Sell|
|Technical Indicators||Sell||Sell||Strong Buy||Strong Sell||Strong Sell|
|Summary||Sell||Neutral||Buy||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Belt Hold Bearish||15||Current|
|Belt Hold Bearish||30||Current|
|Deliberation Bearish||1D||2||Sep 12, 2019|
|Doji Star Bearish||1D||2||Sep 12, 2019|
|Gravestone Doji||1D||2||Sep 12, 2019|
Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.